{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T15:42:32Z","timestamp":1766504552540},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>While <jats:sup>18<\/jats:sup>F-FDG PET\/CT yields valuable prognostic information for patients in first-line therapy of multiple myeloma (MM), its prognostic relevance in relapse is not established. Available studies of relapsed MM describe prognostic thresholds for frequently used PET\/CT parameters that are significantly higher than those identified in the first-line setting. The purpose of this study was to evaluate the prognostic role of PET\/CT in relapsed MM, based on parameters used in the first-line setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Our retrospective study included 36 patients with MM who had received autologous or allogeneic stem cell transplantation, suffered at least one relapse, and underwent FDG-PET\/CT at relapse. Number of focal bone lesions (FL), maximal standardised uptake value (SUVmax), and presence of PET-positive extramedullary lesions (EMD) were analysed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>For the number of FLs, the prognostic value was demonstrated with a cut-off of\u2009&gt;\u20093 (median OS 3.8\u00a0months vs. not reached, p\u2009=\u20090.003). Median OS of patients with SUVmax\u2009\u2264\u20094 was not reached, while it was 3.9\u00a0months in patients with SUVmax\u2009&gt;\u20094 (p\u2009=\u20090.014). Presence of EMD was a significant prognostic parameter too, with median OS of 3.6\u00a0months versus not reached (p\u2009=\u20090.004). The above-mentioned parameters showed prognostic significance for PFS as well. Combination of higher ISS stage and PET\/CT parameters identified patients with particularly short OS (3.7\u00a0months vs. not reached, p\u2009&lt;\u20090.001) and PFS (3.6 vs. 11.7\u00a0months p\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The PET\/CT parameters SUVmax\u2009&gt;\u20094, nFL\u2009&gt;\u20093, and presence of EMD identify patients with poor prognosis not only in the first-line setting but also in relapsed MM.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12880-022-00788-4","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T17:02:44Z","timestamp":1649091764000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["18F-FDG-PET\/CT in relapsed multiple myeloma: Are prognostic thresholds different from first-line therapy?"],"prefix":"10.1186","volume":"22","author":[{"given":"Romans","family":"Zukovs","sequence":"first","affiliation":[]},{"given":"Christina","family":"Antke","sequence":"additional","affiliation":[]},{"given":"Eduards","family":"Mamlins","sequence":"additional","affiliation":[]},{"given":"Lino Morris","family":"Sawicki","sequence":"additional","affiliation":[]},{"given":"Annemarie","family":"Mohring","sequence":"additional","affiliation":[]},{"given":"David","family":"Lopez y Niedenhoff","sequence":"additional","affiliation":[]},{"given":"Amelie","family":"Boquoi","sequence":"additional","affiliation":[]},{"given":"Mustafa","family":"Kondakci","sequence":"additional","affiliation":[]},{"given":"Gerald","family":"Antoch","sequence":"additional","affiliation":[]},{"given":"Hans-Wilhelm","family":"M\u00fcller","sequence":"additional","affiliation":[]},{"given":"Roland","family":"Fenk","sequence":"additional","affiliation":[]},{"given":"Rainer","family":"Haas","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,4,4]]},"reference":[{"issue":"8","key":"788_CR1","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"issue":"9983","key":"788_CR2","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","volume":"385","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig C, Knop S, Bornh\u00e4user M. Multiple myeloma. Lancet. 2015;385(9983):2197\u2013208. https:\/\/doi.org\/10.1016\/S0140-6736(14)60493-1.","journal-title":"Lancet"},{"issue":"6","key":"788_CR3","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","volume":"20","author":"J Hillengass","year":"2019","unstructured":"Hillengass J, Usmani S, Rajkumar SV, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20(6):e302\u201312. https:\/\/doi.org\/10.1016\/S1470-2045(19)30309-2.","journal-title":"Lancet Oncol"},{"issue":"4","key":"788_CR4","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo M, Terpos E, Nanni C, et al. Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18(4):e206\u201317. https:\/\/doi.org\/10.1016\/S1470-2045(17)30189-4.","journal-title":"Lancet Oncol"},{"issue":"1095","key":"788_CR5","doi-asserted-by":"publisher","first-page":"20180768","DOI":"10.1259\/bjr.20180768","volume":"92","author":"T Barwick","year":"2019","unstructured":"Barwick T, Bretsztajn L, Wallitt K, Amiras D, Rockall A, Messiou C. Imaging in myeloma with focus on advanced imaging techniques. Br J Radiol. 2019;92(1095):20180768. https:\/\/doi.org\/10.1259\/bjr.20180768.","journal-title":"Br J Radiol"},{"issue":"2","key":"788_CR6","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3390\/ijms18020445","volume":"18","author":"C Bailly","year":"2017","unstructured":"Bailly C, Leforestier R, Jamet B, et al. PET imaging for initial staging and therapy assessment in multiple myeloma patients. Int J Mol Sci. 2017;18(2):445. https:\/\/doi.org\/10.3390\/ijms18020445.","journal-title":"Int J Mol Sci"},{"key":"788_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00259-017-3730-4","volume":"44","author":"C Nanni","year":"2017","unstructured":"Nanni C, Zamagni E. Therapy assessment in multiple myeloma with PET. Eur J Nucl Med Mol Imaging. 2017;44:111\u20137. https:\/\/doi.org\/10.1007\/s00259-017-3730-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"23","key":"788_CR8","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","volume":"118","author":"E Zamagni","year":"2011","unstructured":"Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989\u201395. https:\/\/doi.org\/10.1182\/blood-2011-06-361386.","journal-title":"Blood"},{"issue":"19","key":"788_CR9","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","volume":"21","author":"E Zamagni","year":"2015","unstructured":"Zamagni E, Nanni C, Mancuso K, et al. PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma. Clin Cancer Res. 2015;21(19):4384\u201390. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0396.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"788_CR10","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.bbmt.2015.03.001","volume":"21","author":"F Patriarca","year":"2015","unstructured":"Patriarca F, Carobolante F, Zamagni E, et al. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21(6):1068\u201373. https:\/\/doi.org\/10.1016\/j.bbmt.2015.03.001.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"788_CR11","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1182\/blood-2012-08-451690","volume":"121","author":"SZ Usmani","year":"2013","unstructured":"Usmani SZ, Mitchell A, Waheed S, et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013;121(10):1819\u201323. https:\/\/doi.org\/10.1182\/blood-2012-08-451690.","journal-title":"Blood"},{"issue":"21","key":"788_CR12","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1182\/blood.V124.21.3983.3983","volume":"124","author":"M Beksac","year":"2014","unstructured":"Beksac M, Gunduz M, Ozen M, Bakanay Ozturk S, Kucuk O, Ozkan E. Impact of PET-CT response on survival parameters following autologous stem cell transplantation among patients with multiple myeloma: comparison of two cut-off values. Blood. 2014;124(21):3983\u20134083. https:\/\/doi.org\/10.1182\/blood.V124.21.3983.3983.","journal-title":"Blood"},{"issue":"1","key":"788_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00259-018-4114-0","volume":"46","author":"SH Jung","year":"2019","unstructured":"Jung SH, Kwon SY, Min JJ, et al. 18F-FDG PET\/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System. Eur J Nucl Med Mol Imaging. 2019;46(1):107\u201315. https:\/\/doi.org\/10.1007\/s00259-018-4114-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"788_CR14","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3324\/haematol.2017.177139","volume":"103","author":"FE Davies","year":"2018","unstructured":"Davies FE, Rosenthal A, Rasche L, et al. Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. Haematologica. 2018;103(6):1047\u201353. https:\/\/doi.org\/10.3324\/haematol.2017.177139.","journal-title":"Haematologica"},{"issue":"10","key":"788_CR15","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","volume":"114","author":"TB Bartel","year":"2009","unstructured":"Bartel TB, Haessler J, Brown TLY, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114(10):2068\u201376. https:\/\/doi.org\/10.1182\/blood-2009-03-213280.","journal-title":"Blood"},{"issue":"2","key":"788_CR16","first-page":"619","volume":"12","author":"C Wang","year":"2019","unstructured":"Wang C, Wu L, Sun C, Zhang Y. Clinical relevance of PET\/CT in patients with newly diagnosed multiple myeloma. Int J Clin Exp Pathol. 2019;12(2):619\u201327.","journal-title":"Int J Clin Exp Pathol"},{"issue":"3","key":"788_CR17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3348\/kjr.2018.19.3.481","volume":"19","author":"SH Moon","year":"2018","unstructured":"Moon SH, Choi WH, Yoo IR, et al. Prognostic value of baseline18F-fluorodeoxyglucose PET\/CT in patients with multiple myeloma: a multicenter cohort study. Korean J Radiol. 2018;19(3):481\u20138. https:\/\/doi.org\/10.3348\/kjr.2018.19.3.481.","journal-title":"Korean J Radiol"},{"issue":"17","key":"788_CR18","doi-asserted-by":"publisher","first-page":"7381","DOI":"10.18632\/oncotarget.2290","volume":"5","author":"C Lapa","year":"2014","unstructured":"Lapa C, L\u00fcckerath K, Malzahn U, et al. 18FDG-PET\/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation. Oncotarget. 2014;5(17):7381\u201391. https:\/\/doi.org\/10.18632\/oncotarget.2290.","journal-title":"Oncotarget"},{"issue":"1","key":"788_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1080\/10428194.2018.1459602","volume":"60","author":"B Jamet","year":"2019","unstructured":"Jamet B, Bailly C, Carlier T, et al. Added prognostic value of FDG-PET\/CT in relapsing multiple myeloma patients. Leuk Lymphoma. 2019;60(1):222\u20135. https:\/\/doi.org\/10.1080\/10428194.2018.1459602.","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"788_CR20","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5.","journal-title":"Lancet Oncol"},{"issue":"12","key":"788_CR21","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.2967\/jnumed.112.106500","volume":"53","author":"R Fonti","year":"2012","unstructured":"Fonti R, Larobina M, Del Vecchio S, et al. Metabolic tumor volume assessed by18F-FDG PET\/CT for the prediction of outcome in patients with multiple myeloma. J Nucl Med. 2012;53(12):1829\u201335. https:\/\/doi.org\/10.2967\/jnumed.112.106500.","journal-title":"J Nucl Med"},{"issue":"25","key":"788_CR22","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"P Moreau","year":"2017","unstructured":"Moreau P, Attal M, Caillot D, et al. Prospective evaluation of magnetic resonance imaging and [18F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial. J Clin Oncol. 2017;35(25):2911\u20138. https:\/\/doi.org\/10.1200\/JCO.2017.72.2975.","journal-title":"J Clin Oncol"},{"issue":"1","key":"788_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00277-019-03852-2","volume":"99","author":"R Fonti","year":"2020","unstructured":"Fonti R, Pellegrino S, Catalano L, Pane F, Del Vecchio S, Pace L. Visual and volumetric parameters by 18F-FDG-PET\/CT: a head to head comparison for the prediction of outcome in patients with multiple myeloma. Ann Hematol. 2020;99(1):127\u201335. https:\/\/doi.org\/10.1007\/s00277-019-03852-2.","journal-title":"Ann Hematol"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-022-00788-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-022-00788-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-022-00788-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T17:03:12Z","timestamp":1649091792000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-022-00788-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,4]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["788"],"URL":"https:\/\/doi.org\/10.1186\/s12880-022-00788-4","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,4]]},"assertion":[{"value":"21 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare that the investigations were carried out following the rules of the Declaration of Helsinki of 1975, revised in 2013. According to point 23 of this declaration, approval of an ethics committee was sought prior to the study. The approval was provided by the Ethics Committee of the Medical Faculty of Heinrich Heine University Dusseldorf, Germany (vote nr. 2020-906). Patient consent was waived due to the monocentric and retrospective nature of the study and due to the following considerations: many patients were already deceased at the time of data collection. Furthermore, all diagnostic procedures were performed as part of routine medical care. The monocentric study was conducted by the physicians at the University Hospital Dusseldorf, and no data were shared with or analysed by external parties. All data was anonymized prior to analysis. No data that could directly or indirectly identify the patients is included for publication. These aspects were specifically considered by the Ethics Committee of the Medical Faculty of Heinrich Heine University Dusseldorf, Germany, in vote nr. 2020-906.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}